Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin, Lilly Partnership Tested By Lilly GLP-1 Project

This article was originally published in The Pink Sheet Daily

Executive Summary

Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.
Advertisement

Related Content

Lilly, Amylin Expand Byetta Deal: Vote Of Confidence Or Down Payment?
Lilly, Amylin Expand Byetta Deal: Vote Of Confidence Or Down Payment?
“Unhappy” BMS To ImClone: Erbitux, Follow-on Still Ours
The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals
Novo’s Liraglutide Gets Advisory Committee Review; Is Byetta To Blame?
Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says
Miscommunicating Risk: The Byetta Disconnect
Miscommunicating Risk: The Byetta Disconnect
Amylin CEO: Firm Can Do Better With Byetta

Topics

Advertisement
UsernamePublicRestriction

Register

PS068333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel